Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma
Oncology Research and Treatment · 2023
DOI: 10.1159/000530801 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Jule Cecilia Artzenroth und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Ribose, Adenocarcinoma. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Introduction
Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted therapy may be a suitable treatment for selected patients, but its efficacy remains elusive. Case Presentation: Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-line therapy, including a programmed cell death ligand 1 (PD-L1) inhibitor, next-generation sequencing of a tumor sample was performed to identify possible molecular targets. A mutation in RAD51C, a member of the homology-directed repair (HDR) system, was identified in addition to high PD-L1 expression. As a result, therapy with the poly-(ARD-Ribose) polymerase (PARP) inhibitor olaparib and the programmed cell death protein 1 (PD1)-inhibitor pembrolizumab was initiated. A durable partial response lasting for more than 17 months was observed. A second molecular profiling from a newly occurring subcutaneous metastasis showed a loss of FGF10 but no fluctuations in the gene alteration of RAD51C and SMARCA4. Interestingly, the new lesion showed HER2-positivity (immunohistochemistry 3+ and fluorescence in situ hybridization [FISH]-positivity) in 30% of tumor cells.
Conclusion
In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinical trials to analyze the efficacy of PARP inhibitor combinations in EGA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany.
- Radiologische Praxis am Israelitisches Krankenhaus, Hamburg, Germany.
Zitieren
APA
Artzenroth, J. C., Tintelnot, J., Haag, G. M., Gökkurt, E., Steffens, J., & Stein, A. (2023). Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma. Oncology Research and Treatment. https://doi.org/10.1159/000530801
Vancouver
Artzenroth JC, Tintelnot J, Haag GM, Gökkurt E, Steffens J, Stein A. Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma. Oncology Research and Treatment. 2023. doi:10.1159/000530801
BibTeX
@article{Artzenroth2023,
author = {Artzenroth, Jule Cecilia and Tintelnot, Joseph and Haag, Georg Martin and Gökkurt, Eray and Steffens, Johann and Stein, Alexander},
title = {Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma},
journal = {Oncology Research and Treatment},
year = {2023},
doi = {10.1159/000530801}
}
EUVIMED